

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort NeuroTech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on March 28, 2024, the Company has resolved to grant share options (the “**Options**”) to 50 eligible participants (the “**Grantees**”), to subscribe for up to an aggregate of 2,191,000 ordinary shares of the Company of US\$0.00002 each (the “**Shares**”) in the capital of the Company pursuant to the share scheme (the “**Share Scheme**”) adopted by the Company on July 12, 2023, subject to the acceptance of the Grantees.

Details of the Options are as follows:

Date of grant	March 28, 2024 (the “ Date of Grant ”)
Number of Grantees	50 Grantees (including 3 Directors and other 47 employees of the Group)
Exercise price of the Options granted	HK\$8.496 per Share, representing the highest of: (i) the closing price of HK\$8.38 per Share as stated in the daily quotations sheet issued by The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) on the Date of Grant;

- (ii) the average closing price of HK\$8.496 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and
- (iii) the nominal value of a Share of US\$0.00002

Number of Options granted An aggregate of 2,191,000 Options, among which, 444,000 Options were granted to 3 Directors and the remaining 1,747,000 Options were granted to other employees of the Group (each Option shall entitle the holder of the Option to subscribe for one Share)

Validity period of the Options Ten (10) years from the Date of Grant

Vesting period of the Options All of the options shall be vested on the fifth anniversary year of the Date of Grant.

Performance targets The vesting of the Options is not subject to any performance targets.

The purpose of the Share Scheme is to provide incentive to eligible participants in order to promote the development and success of the business of the Group. The Options to be granted will give the Grantees an opportunity to have a personal stake in the Company and will help motivate the Grantees in optimizing their performance and efficiency. The number of Options to be granted are based on the work performance and potential of the Grantees and no additional performance target is imposed before the Options are vested to the Grantees. In view of the above, the remuneration committee of the Company (the “**Remuneration Committee**”) considered the grant of Options aligned with the purpose of the Share Scheme.

Clawback mechanism The Options granted will be subject to the clawback mechanism as set out in the Share Schemes and offer letter of the grant of Options as determined by the Board, in particular, the lapse of Options upon cessation of employment of the Grantee and the cancellation of Options at the discretion of the Board.

Among the Options granted above, a total of 444,000 Options were granted to 3 Directors, details of which are as follows:

Name	Position	Number of Options
Xie Zhiyong	Executive Director	239,000
Wang Yiqun Bruce	Executive Director	125,000
Sun Qingwei	Non-executive Director	80,000

The grant of Options to the above Directors has been approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules. None of the grants of Options will be subject to approval by independent shareholders of the Company.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries: (i) no financial assistance has been provided by the Group to the Grantees for the purchase of shares under the Share Scheme; (ii) save for Mr. Xie Zhiyong, Mr. Wang Yiqun Bruce and Mr. Sun Qingwei, none of the other Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; and (iii) none of the Grantees is a related entity participant or service provider (as defined under the Listing Rules); and (iv) none of the Grantees is a participant with options and awards granted and to be granted exceeding the 1% individual limit under the Listing Rules.

Subsequent to the grant of Options, the number of Shares available for future grants pursuant to the Share Scheme is 54,925,810 Shares and, among which, the number of Shares available for future grant under the service provider limit of the Share Scheme is 5,826,581 Shares.

By Order of the Board
MicroPort NeuroTech Limited
Dr. Chang Zhaohua
Chairman and Non-executive Director

Hong Kong, 28 March 2024

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Chang Zhaohua, Mr. Wang Lin, Ms. Wu Xia and Mr. Sun Qingwei as the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung as the independent non-executive directors.